Atrium Therapeutics Doses First Patient in Corventis™, the First Interventional Clinical Trial for People Living with PRKAG2 Syndrome
— Global Phase 1/2 trial will evaluate ATR 1072 in approximately 37 participants — — Initial proof of concept data expected in second half of 2027 — SAN DIEGO, Oct. 27, 2026 /PRNewswire/ — Atrium […]
